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ABSTRACT The failure to induce self-tolerance of simian
virus 40 large tumor antigen (T antigen) expressed in the
pancreatic (3 cells of transgenic mice results in an autoimmune
response against this protein and the cells that synthesize it. In
every transgenic mouse with delayed onset of T-antigen expres-
sion and consequent nontolerance, B cells, T cells, and mac-
rophages are attracted to and infiltrate the pancreatic islets. In
contrast, the incidence, onset, and intensity of the B-cell
response to produce anti-T-antigen autoantibodies vary con-
siderably with genetic background. Thus the initial attraction
of lymphocytes to the cells synthesizing a non-self antigen can
be separated from the activation of a B-cell response against it.
Haplotypes of the major histocompatibility complex (MHC)
differentially influence the character of the autoimmune re-
sponse, with H-2d and H-2k conferring a high incidence of
humoral autoimmunity. Additional non-MHC linked genes are
also implicated in control of the B-cell response.
It is well established that the immune system develops a
capacity to discriminate between foreign and self entities (1).
The importance of tolerance toward self can be seen in a
number of diseases of apparent autoimmune nature, in which
tissues are selectively destroyed by the immune system (2).
Common features to many autoimmune diseases are the
development of circulating autoantibodies that are reactive to
components of the tissue undergoing destruction (3) and the
correlation of the autoimmune phenotype with specific hap-
lotypes of the major histocompatibility complex (MHC)
(4-6).
Recently, transgenic mice have been used in a number of
experiments designed to test theories of self-tolerance or
autoimmunity (7). We have developed one such transgenic
model, which has allowed aspects ofthe relationship between
self-tolerance and autoimmunity to be examined (8-10). The
rat insulin gene regulatory region was used to selectively
express the large tumor antigen (T antigen, or Tag) of simian
virus 40 (SV40) in the insulin-producing A3 cells of the
pancreatic islets in several lines of transgenic mice (RIP-Tag
mice). Every transgenic individual eventually succumbs to
pancreatic /3-cell tumors. Besides this commonality, the
lineages can be subdivided into two classes. In the first class,
mice begin to express the hybrid gene during embryogenesis
(developmental onset). In contrast, in several other lines, the
insulin/T-antigen gene is first activated in a heterogeneous
subset of the p cells beginning at 10-12 weeks after birth
(delayed onset). The immune system responds in two differ-
ent ways to the two distinct patterns of expression among
these lineages (9). Mice with developmental onset of expres-
sion are nonresponsive (or self-tolerant) to this new self
protein. In contrast, mice in the lines with delayed onset of
expression are fully responsive upon immunization with
purified large T protein. This nontolerance to a new A-cell
antigen is associated with the development of a spontaneous
autoimmune response against T antigen and the cells that
synthesize it, as evidenced by the appearance of circulating
antibodies against the protein and cellular infiltration of the
pancreatic islets. It is of note that the insulinomas that
develop in these mice manage to escape this autoimmune
response and, as a result, the mice become hyperinsulinemic
and do not evidence frank diabetes. Here we examine the
time course of the autoimmune response, as evidenced by the
appearance of autoantibodies, a property that can be moni-
tored noninvasively over time, and assess the possibility that
genetic factors, including the MHC, contribute to the induc-
tion of autoimmunity.
MATERIALS AND METHODS
Mice. The inbred strains C57BL/6, C57BL/10, DBA/2,
and C3HeB/Fe, the congenic strains B1O.BR and B1O.D2,
and the hybrid C57BL/6 x DBA/2 F1 mice (B6D2F1) were
purchased from The Jackson Laboratory. The RIP1-Tag3 line
of transgenic mice has been described (8).
Determination of H-2 Haplotype. Restriction fragment
length polymorphisms for BstEII and Pvu II at the Ap locus
of the H-2b and H-2d haplotypes, visualized by hybridization
toA cDNA probe, were used to determined H-2 composition
of transgenic mice (11, 12).
Immunohistochemistry. T antigen was detected as de-
scribed (9). Lymphocyte typing was performed on adjacent
cryostat sections with rat monoclonal antibodies (mAbs)
directed against the Lyt2 (clone 53.6.7), L3T4 (clone GK1.5),
B220 (clone 6B2), and Macl (clone M170) surface determi-
nants of the cytotoxic T cells, helper T cells, B cells, and
macrophages, respectively, using the alkaline phosphatase
system (ABC-AP kit, Vector Laboratories).
Quantitation of Anti-T-Antigen Autoantibodies. Blood sam-
ples were collected from the orbital plexus of transgenic or
appropriate control mice. Solid-phase radioimmunoassays
(RIA) were performed in Dynatech 96-well microtiter plates
coated with purified SV40 T protein (13, 14). Plates were
blocked with 1% bovine serum albumin and serial dilutions of
test and control sera were absorbed onto coated plates.
Bound antibody was allowed to react with 1251-labeled rabbit
anti-mouse IgG antibody (Amersham), and individual wells
were cut out and assayed for radioactivity in a 1272 Clin-
gamma counter (LKB). The titer is defined as the dilution of
a test serum that results in 50% of the maximum signal
obtained with mAb 416 (14), an anti-Tag mouse mAb used as
a positive control. The titer of the positive control antibody
Abbreviations: MHC, major histocompatibility complex; SV40, sim-
ian virus 40; T antigen or Tag, large tumor antigen; mAb, monoclonal
antibody.
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was stable (within 20%) within a period of >18 months when
measured in this assay.
RESULTS
Genetic Control of the B-Cell Response in RIP1-Tag3 Mice.
Transgenic mice ofthe RIP1-Tag3, RIP1-Tag4, and RIR-Tagl
lines, which are characterized by the delayed onset of T-
antigen expression, develop antibody responses against this
,8-cell antigen with variable incidence (35-60%) (9). It is
conceivable that the incomplete penetrance results from
genetic differences. The founders of these transgenic lines
were constructed in F2 hybrids between C57BL/6 and DBA/
2 inbred mice, and for the first few generations (six) the lines
were propagated by brother/sister intercrosses and also by
backcrosses to C57BL/6 and B6D2F1 mice (8). Therefore, we
first tested whether the C57BL/6 and DBA/2 genetic back-
grounds could differentially affect the B-cell response in the
RIP1-Tag3 line. Randomly selected RIP1-Tag3 males were
mated with females of either the C57BL/6 or DBA/2 parental
strains, and the development of serum antibodies reacting
with SV40 T antigen in the transgenic progeny was monitored
in samples collected periodically over a period of 30 weeks.
Virtually all of the transgenic progeny derived from the
DBA/2 cross developed high levels of serum anti-Tag anti-
bodies by 20-25 weeks of age. In contrast, a smaller fraction
(ca. 30%) oftransgenic animals originating from the C57BL/6
cross developed humoral responses against Tag (Fig. 1).
Association of Autoimmunity with MHC Haplotype. Subse-
quent experiments sought to characterize the DBA/2 locus
(or loci) that stimulates the autoantibody response in RIP1-
Tag3 mice. One candidate is the MHC. The H-2 haplotypes
of a number of RIP1-Tag3 mice were determined, and broth-
ers and sisters homozygous for the H-2 b allele were used to
derive an H-2 b/b subline (RIP1-Tag3B), which has been
maintained by continuous backcrossing to C57BL/6. RIP1-
Tag3B males were mated to B6D2F1 (H-2 bid) hybrid females,
and the activation of the B-cell response in their transgenic
progeny was monitored periodically as before. Twenty of 27
mice (74%) developed autoantibodies by 30 weeks of age
(Fig. 1). To test whether a specific MHC haplotype was being
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cosegregated with the autoimmune phenotype, the MHC
haplotypes of a subset ofthe transgenic progeny derived from
this cross were determined. Interestingly, among the H-2b/b
offspring only 38% (5 of 13) had autoantibodies by 30 weeks
of age. In contrast, a significantly higher incidence of auto-
antibodies was observed in mice carrying H-2b and H-2d
haplotypes, where 75% (9 of 12 mice) evidenced serum
antibodies reacting with T antigen at 30 weeks (Fig. 2).
The B-Cell Response Is Influenced by the MHC and a Second
Locus. To further characterize the apparent association of the
MHC haplotype with the incidence of B-cell autoimmunity,
additional combinations of haplotypes were constructed by
crossing RIP1-Tag3B mice with different histocompatibility
congenic strains and with distinct inbred strains. RIP1-Tag3B
males were crossed to C57BL/10 (H_2b), to the congenic
strains B10.D2 (H-2d) and B10.BR (H-2k), and also to DBA/2
(H-2d) and C3HeB (H-2k). The incidence of autoantibodies in
the transgenic progeny from these outcrosses was assessed,
and the data are summarized in Table 1. When the H-2 b/b
transgenics derived from crosses to C57BL/6 or C57BL/10
are compared to the H-2 bld or H-2b/k offspring derived from
crosses to C57BL/10 congenic strains, it can be seen that the
d and the k haplotypes confer a higher incidence of autoanti-
bodies ('16% for b/b compared to -56% for bid and b/k).
These results confirm the differential effects ofMHC alleles
on the activation of the B-cell response. However, the same
haplotype combinations conferred a 100% incidence of au-
toimmunity when constructed by crossing RIP1-Tag3B mice
to either DBA/2 or C3HeB. If one assumes identity ofMHC
haplotypes between B1O.BR and C3HeB (which differ at the
Tla and Qa-J loci), this observation implies that a second
non-MHC locus contributes to the control of the B-cell
response. This conclusion is consistent with the results
obtained with the B6D2F1 cross, where the H_2b and H_2d
alleles are reassorting along with the other chromosomes
from the C57BL and DBA/2 backgrounds. In this cross 67%
of the H_2bld progeny evidenced autoantibodies at a compa-
rable age (25 weeks), which is significantly lower than the
100o incidence in the DBA/2 and C3HeB crosses. Thus the
incidence of B-cell activation to produce anti-T-antigen auto-
antibodies in these transgenic mice is influenced by at least
-
_
FIG. 1. Effect of parental genetic background on development of Tag autoantibodies in
RIP1-Tag3 mice. (Upper) Time course of serum IgG antibodies reacting with T antigen in
RIP1-Tag3 mice derived from DBA/2 (x D2), C57BL/6 (x B6), or B6D2F1 (x B6D2F1)
crosses. Each dot represents the analysis ofserum taken from one individual at the time point
indicated. (Lower) The fraction of autoantibody-positive mice at a given age was calculated
from the data above as a cumulative percentage ofanimals that had developed autoantibodies
at or prior to this age. The crosses were to DBA/2 (o), C57BL/6 (e), and B6D2F1 (o). The
statistical significance of the associations between anti-Tag antibodies and genetic back-
ground among 25-week-old transgenic mice was estimated from 2 x 2 contingency tables: for
the cross to C57BL/6 (x C57BL/6) vs. the cross to DBA/2, x2 = 34.8, P < 0.0001; for x
C57BL/6 vs. x B6D2F1, x2 = 7.%, P < 0.01; and for x DBA/2 vs. x B6D2F1, x2 = 18.76,
P < 0.0001.10 Age
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weeks of age, which is 2 months after T-antigen expression
ensues in a subset of the 13 cells. Although islets in every
mouse attracted leukocyte infiltration, only a fraction of the
islets (10-40%) became infiltrated. Preliminary observations
suggest that this nonuniform pattern of islet infiltration cor-
relates with differences in the density of Tag-expressing 13
cells in different islets. The infiltrated islets were seen to have
representation by B lymphocytes, CD8' T cells, CD4' T
cells, and infrequent macrophages, in contrast to the islets of
normal mice, where none of these leukocytes could be found
in association with the islets. Examples of the analysis of
infiltrated islets are shown in Fig. 3, which presents an
autoantibody-negative mouse with an H-2 b/bMHC haplotype
and an autoantibody-positive mouse with an H-2b/a haplo-
type.
30 (weeks)
100 r
0
0
50
0
0
10
Age
20 30 (weeks)
FIG. 2. Relation of humoral autoimmunity to segregating H-2
haplotype. (Upper) RIP1-Tag3B males (of the N1 backcross to
C57BL/6) were outcrossed to B6D2F1 females (H-2bld) and their
transgenic offspring were analyzed for T-antigen autoantibodies. The
H-2 haplotypes of the transgenic progeny were determined by
analysis for a restriction fragment length polymorphism in the A4
locus. The time courses of autoantibodies arising in RIP1-Tag3 mice
either homozygous for the H-2b haplotype (o) or harboring H-2b and
H-2d alleles (0) are shown here. (Lower) Incidence of humoral
autoimmunity among RIP1-Tag3 mice carrying the H_2b/b (e) or
H_2b/d (o) haplotype. The significance of the differences in inci-
dences at 25 weeks of age is as follows: for the H-2b/b progeny of x
B6D2F1 vs. the H_2b/d progeny of x B6D2F1, x2 = 8.08, P < 0.01;
for comparing H-2b/b progeny of x B6D2Fj with those of x DBA/2
(H-2b/d), x2 = 24.8, P <0.0001; for the H-2bId progeny of x B6D2F1
vs. progeny of x DBA/2 (H_2b/d), x2 = 7.09, P < 0.012; and for
H_2b/d progeny of x B6D2F1 vs. progeny of x C57BL/6 (H-2b/b), x2
= 14.25, P < 0.0005.
two loci that are differential between C57BL and either
DBA/2 or C3HeB. One is clearly linked to the MHC, and the
other(s) appears to assort independently from it.
Characteristics of the Leukocyte Response to T Antigen in
Cells. The initial characterization of the autoimmune re-
sponse in the RIP1-Tag3 mice revealed cellular infiltration
within the islets of mice with circulating autoantibodies to T
antigen (9). We have now characterized the cell types infil-
trating the islets. Serial sections of transgenic and control
pancreases were stained with hematoxylin/eosin or with
mAbs that recognize the Lyt2 (CD8), L3T4 (CD4), B220, or
Maci surface determinants on cytotoxic T cells, helper/
inducer T cells, B cells, or macrophages, respectively. The
analysis has revealed that leukocyte infiltration can be de-
tected in the islets of anti-Tag autoantibody-positive and
autoantibody-negative mice in each MHC background by 20
DISCUSSION
RIP1-Tag3 mice inherit a self antigen, SV40 T antigen, whose
expression in the pancreatic cells is inappropriately delayed
into adulthood (8), thereby failing to induce immunological
self-tolerance (9). The synthesis ofthis non-selfantigen in the
pancreatic 13 cells is clearly apparent to the immune system,
as it provokes an autoimmune response against the transgenic
antigen and the pancreatic cells. Activation of the immune
response against this autoantigen is modulated by the MHC
and by additional genetic and/or epigenetic factors.
Lymphocyte Attraction Does Not Obligate B-Cell Activation.
In all combinations of MHC haplotypes and genetic back-
grounds tested thus far, T antigen elicits abnormal infiltration
of the islets by the four major classes of leukocytes within 2
months of its appearance in adult 13 cells. However, the
infiltration is not sufficient for induction of the B-cell au-
toimmune response against T antigen, given that every mouse
evidences some degree ofleukocyte infiltration, and yet by 20
weeks of age only 43% of the H-2b/d mice developed anti-
bodies, and a majority of the H-2b/b mice never develop a
detectable humoral response. The inactive status of the
infiltrating B cells in autoantibody-negative mice is obvious.
With regard to T cells and macrophages, their state of
activation is presently unresolved. There are clear signs of
,1-cell destruction in occasional islets of mice at 20-25 weeks
of age, which suggests focal activation of the infiltrating cells
(e.g., Fig. 3). Taken together these observations indicate that
homing of leukocytes to the site of a perceived abnormality
can be separated from the activation ofthose immune cells to
destroy the cells that have attracted their attention.
MHC Association with B-Cell Activation. The B-lympho-
cyte response toward the transgenic 13-cell protein ensues at
high frequency when the delayed onset of expression of the
transgene is combined with the H-2d or H-2k haplotypes of
the major histocompatibility complex. In contrast, RIP1-
Tag3 mice homozygous for the H-2b haplotype develop a
humoral response much less frequently. Furthermore, the
intensity of the B-cell response is markedly weaker in the
H-2 b/b mice, as seen in the serum autoantibody titers, which
are characteristically 100-fold lower than those arising in
transgenic mice with H_2bld or H_2b/k haplotype. These
results might suggest an involvement of the I-E region, since
the H-2b MHC encodes a defective Ea gene (15, 16) and, as
a result, H-2 b/b mice do not express a functional I-E het-
erodimer on the cell surface (16). However, if I-E is involved,
its absence does not completely abrogatepresentation ofTag
peptides by class II, since -16% of H-2 b/b RIP1-Tag3 mice
eventually develop anti-Tag autoantibodies (Table 1).
An Additional Locus Influences the B-Cell Autoimmune
Response. Although a major component of the genetic control
of the B-cell autoimmune response against T antigen is linked
to the MHC, there were statistically significant differences in
the incidence of autoantibodies among transgenic mice with
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FIG. 3. Leukocyte infiltration of
pancreatic islets in RIP1-Tag3 mice.
H-2b/b RIP1-Tag3 males from the
B6D2F1 outcross were mated to either
CS7BL/6 or DBA/2 females, and the
transgenic offspring were sacrificed
and analyzed histologically. Adjacent
pancreatic sections have been stained
by hematoxylin/eosin (HE) or immuno-
stained with mAbs specific for leuko-
cyte surface determinants: Lyt2 (cyto-
toxic/suppressor T cells), L3T4 (helper
T cells), B220 (B cells), and Macl (mac-
rophages). In the three examples shown
the islets are located next to a pancre-
atic duct. (x80.) (Left) Typical islet of
a nontransgenic DBA/2 mouse. (Cen-
ter) Infiltrated islet of a 5-month-old
RIP1-Tag3 x C57BL/6 (H-2b/b) mouse
that did not have a detectable titer of
circulating anti-Tag autoantibodies.
(Right) Infiltrated islet ofa 5-month-old
RIP1-Tag3 X DBA/2 (H_2b/d) mouse
that had a high titer of circulating anti-
Tag autoantibodies.
the same MHC haplotypes (either H-2b/d or H-2b/ but
differing in strain background (Table 1). In addition, it is
remarkable that only a small fraction (-16%) of the H_2b/b
mice eventually develop a B-cell response against T antigen,
despite the development of pancreatic P-cell tumors express-
ing this nontolerant antigen. These observations together
Table 1. The MHC and a second locus influence the
autoantibody response in RIP1-Tag3 mice
MHC
haplotype of Autoantibody Time of
Outcross progeny incidence (%) sampling, weeks
C57BL/6 b/b 4/46 (9) 25
C57BL/10 b/b 8/35 (23) 16-28
B1M.D2 bid 7/13 (54) 23-32
B10.BR b/k 4/7 (57) 25
DBA/2 bid 27/27 (100) 25
C3HeB b/k 9/9 (100) 25
RIP1-Tag3B males were mated to females of the indicated strains,
and the incidence of autoantibodies was assessed in the transgenic
progeny. A single male from the H-2 b/b subline intercrosses was used
for the B1O.BR and the C3HeB outcrosses; the males used in the
C57BL/10 and the B1O.D2 outcrosses were N2 or N3 C57BL/6
backcrosses from the H-2b/b subline. The data for the CS7BL/6 and
the DBA/2 outcrosses are cumulative of the experiments presented
in Fig. 1 and of a subsequent experiment in which a single male from
the H_2b/b subline intercrosses was used. Haplotypes set in boldface
type indicate the differential MHC haplotype among the genetic
crosses.
support the proposition that an additional allelic locus (or
loci) is involved in regulating activation of the B-cell autoim-
mune response. Although it is possible that these loci act by
subtly affecting the level of T-antigen expression, immuno-
histochemical analysis of islets in 4- to 5-month-old trans-
genic mice from these different strain backgrounds indicates
that each has similar levels and timing of transgene expres-
sion. Among other candidates loci are those that influence
antigen processing (17) or antigen recognition. Precedents for
this latter possibility come from studies implicating specific
allotypes of the T-cell receptor a and ,B chains in human and
animal autoimmunity (reviewed in ref. 6; ref. 18). Alterna-
tively, biases in the T-cell repertoire produced by superan-
tigens such as mls or other agents (19-21) could be influenc-
ing either positive or negative selection ofthe T cells involved
in regulating the B-cell response to T antigen.
Multiple Requirements for Induction of Autoimmunity.
Nontolerance toward T antigen is necessary for the attraction
of leukocytes to the site of its synthesis, since none occurs in
mice of the tolerant lineages RIP1-Tag2 and RIR-Tag2 (10).
However, the leukocyte infiltration induced by this nontol-
erant antigen in RIP-Tag3 mice contrasts with other trans-
genic mouse models where the expression of non-self anti-
gens has been targeted to peripheral tissues. AllogeneicMHC
class I or class II molecules have been expressed in trans-
genic mice in various nonlymphoid tissues, including the
pancreatic 83 cells of the islets of Langerhans (22-25), the
exocrine pancreas (26-28), and also the liver and the kidney
(27). Extrathymic expression of a non-self MHC molecule
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resulted in the establishment of self-tolerance in some cases,
but not in others, as assessed by different in vitro assays.
However, regardless of their tolerance status, there is a
consistent feature in these models: in all cases, the presence
of a non-self MHC molecule did not trigger an autoimmune
response against the tissue where it was expressed. Thus the
model described here is clearly different, since the delayed
expression of a non-MHC antigen, large T antigen, results in
nontolerance and induces leukocyte infiltration ofthe islets of
Langerhans in every RIP1-Tag3 mouse. In two other trans-
genic models, expression of interferon y (IFN-'y) (29) or
influenza virus hemagglutinin (HA) (30) in the pancreatic (3
cells also resulted in autoimmune responses that were con-
comitant with or preceded by abnormalities in the pancreatic
/3 cells themselves. One interpretation of the dichotomy
between the effects ofMHC molecules, on the one hand, and
T antigen/IFN-y/HA, on the other, is that both nontolerance
and other as yet undefined abnormal conditions are necessary
for the induction of an autoimmune response. In this regard,
it is notable that various abnormalities result from expressing
the large T protein in / cells; these include increased /B-cell
senescence, extensive /3-cell proliferation, and neovascular-
ization (31, 32). Perhaps one or another of these abnormal
conditions is necessary in addition to the immunogenic
properties of a nontolerant self antigen to induce leukocyte
infiltration of the islets and their subsequent functional acti-
vation to produce autoantibodies.
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